Aldeyra Therapeutics is a Concord, Massachusetts biotech developing drug candidates for eye and other immune system diseases. ALDX reports earnings on Wed, Nov 4, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 29 | BTIG | Reiterated | Buy | |
| Mar 18 | HC Wainwright & Co. | Downgrade | Hold |
Seasonality
How ALDX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
Whale Options Flow
90DNo whale options trades in ALDX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALDX is in one of them and how their past ALDX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ALDX in an article yet. Here's the latest on the wider market.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company based in Concord, Massachusetts, that develops drug candidates for diseases of the immune system. Its approach uses a family of small molecules called RASP modulators, which act on many proteins at once rather than a single target. Its most advanced candidate, reproxalap, is being studied for dry eye disease and allergic conjunctivitis, and the company is also developing treatments for retinal conditions. It has no approved products yet and plans to sell any future drugs directly or through partners.
- Headquarters
- Concord, MA